InMed Pharmaceuticals Inc.
INM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001728328
In the last 90 days, InMed Pharmaceuticals Inc. insiders filed 4 open-market purchases and 0 sales; 20 institutions reported holding it in 13F filings for Q2 2026, worth $4.18M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding InMed Pharmaceuticals Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Of which not filed for Q1 2022 | Q1 2022 | Change |
|---|---|---|---|---|
| Holders | 18 | 2 | 19 | +3 |
| Shares | 409.8K | 836 | 363.1K | −45.8K (−11.2%) |
| Value | $536.4K | $1.00K | $341.9K | −$193.4K (−36.1%) |
2 institutions that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (4)
Institutions that held InMed Pharmaceuticals Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Empery Asset Management, LP | 61,741 | $58.0K | 0.27% |
| Two Sigma Securities, LLC | 17,979 | $17.0K | 0.00% |
| Geode Capital Management, LLC | 13,905 | $13.0K | 0.00% |
| Millennium Management LLC | 14,069 | $13.0K | 0.00% |
Sold out (1)
Institutions that held InMed Pharmaceuticals Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Citadel Advisors LLC | 11,060 | $14.0K |
Not filed for Q1 2022 yet (2)
Institutions that held InMed Pharmaceuticals Inc. at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Reilly Financial Advisors, LLC | 700 | $1.00K |
| Carroll Financial Associates, Inc. | 136 | $0 |